| Size | Price | Stock | Qty |
|---|---|---|---|
| 1mg |
|
||
| 5mg |
|
||
| 10mg |
|
||
| 25mg | |||
| Other Sizes |
| Targets |
NXT629 targets peroxisome proliferator-activated receptor alpha (PPAR-alpha), a nuclear hormone receptor involved in lipid metabolism and inflammation. The compound acts as a competitive antagonist of PPAR-alpha with an IC₅0 of 77 nM for human PPARalpha. It shows high selectivity over PPARdelta, PPARgamma, ERbeta, GR, and TRbeta.
|
|---|---|
| ln Vitro |
NXT629 (Compound 33) is a strong and selective PPAR-α antagonist with an IC50 of 77 nM for human PPARα and an IC50 between 6.0 and 15 for other nuclear hormone receptors such as PPARδ, PPARγ, Erβ, GR and TRβ, respectively. NXT629 also suppresses PPARα, PPARβ/δ and PPARγ with IC50 of 2.3, 35.1 and 6.9 μM respectively[2].
In vitro, NXT629 inhibits human PPARalpha with an IC₅0 of 77 nM. It shows selectivity over PPARdelta (IC₅0 = 6.0 microM), PPARgamma (IC₅0 = 15 microM), ERbeta (IC₅0 = 15.2 microM), GR (IC₅0 = 32.5 microM), and TRbeta (IC₅0 >100 microM). The compound has potent anti-tumor activity. |
| ln Vivo |
Compound 33, also known as NXT629, had favorable pharmacokinetics in mice and notably decreased the expression of the PPARα target gene Fgf21, or fibroblast growth factor 21, in mice that had been starved [1]. NXT629 (30 mg/kg, intraperitoneally injected once daily for 6 weeks) suppresses the growth of C57Bl/6 mice and delays the growth of subcutaneous SKOV-3 tumors in nude mice. On FGF-induced angiogenesis, NXT629 (30 mg/kg, ip) has negligible anti-angiogenic effects. B16F10 melanoma cells' experimental growth and metastasis to mice lungs is inhibited by NXT629 (3, 30 mg/kg, ip) [2].
In vivo, NXT629 demonstrates significant antitumor activity, slowing the growth of SKOV-3 ovarian cancer and B16F10 melanoma tumors. It exerts weak anti-angiogenic effects. The compound notably decreases the expression of the PPARalpha target gene Fgf21 (fibroblast growth factor 21) in starved mice. NXT629 (30 mg/kg) shows favorable pharmacokinetics in mice. |
| Enzyme Assay |
The in vitro PPAR-alpha antagonist assay uses a reporter gene system with PPAR-alpha ligand-binding domain fused to a GAL4 DNA-binding domain. Cells are transfected with the reporter construct and treated with a PPAR-alpha agonist (such as GW7647) and varying concentrations of NXT629. Luciferase activity is measured to assess antagonist activity. IC₅0 values are calculated from dose-response curves.
|
| Cell Assay |
For in vitro cell-based assays, cancer cell lines (such as SKOV-3 or B16F10) are cultured and treated with NXT629 at various concentrations. Cell proliferation is measured using MTT, CellTiter-Glo, or other viability assays. PPARalpha target gene expression (such as Fgf21) is measured by qRT-PCR to confirm target engagement. Anti-angiogenic effects may be assessed using endothelial cell tube formation assays. Experiments are typically performed in triplicate.
|
| Animal Protocol |
In vivo animal studies for NXT629 typically involve xenograft mouse models using SKOV-3 ovarian cancer or B16F10 melanoma cells. Tumor-bearing mice are administered NXT629 at doses such as 30 mg/kg. Tumor volume is measured periodically using calipers, and tumor growth inhibition is assessed relative to vehicle-treated controls. Fgf21 expression is measured in liver or other tissues to confirm PPARalpha target engagement. Pharmacokinetic studies may also be performed.
|
| ADME/Pharmacokinetics |
Pharmacokinetic properties of NXT629 indicate poor oral bioavailability despite favorable pharmacokinetics in mice. The compound demonstrates significant antitumor activity despite this limitation. The compound is typically formulated for intraperitoneal or intravenous administration in research settings. Further detailed PK parameters would require dedicated studies.
|
| Toxicity/Toxicokinetics |
Toxicological data for NXT629 are not well characterized in the public domain. As a research chemical, standard safety precautions should be observed. The compound is for laboratory use only and not intended for human therapeutic applications. PPAR-alpha antagonists as a class may have potential effects on lipid metabolism and inflammation. Comprehensive toxicity profiling would be required for therapeutic development.
|
| References | |
| Additional Infomation |
NXT629 (CAS# 1454925-59-7) is a potent, selective, and competitive PPAR-alpha antagonist with an IC₅0 of 77 nM. It shows selectivity over PPARdelta, PPARgamma, ERbeta, GR, and TRbeta. The compound has potent anti-tumor activity and inhibits metastasis in animal models. It is used in cancer research and is not approved for clinical use.
|
| Molecular Formula |
C35H39N5O3S
|
|---|---|
| Molecular Weight |
609.780866861343
|
| Exact Mass |
609.277
|
| CAS # |
1454925-59-7
|
| PubChem CID |
71721539
|
| Appearance |
Light yellow to yellow solid powder
|
| LogP |
6.5
|
| Hydrogen Bond Donor Count |
1
|
| Hydrogen Bond Acceptor Count |
6
|
| Rotatable Bond Count |
12
|
| Heavy Atom Count |
44
|
| Complexity |
1060
|
| Defined Atom Stereocenter Count |
0
|
| SMILES |
S(C1C=CC=CC=1)(NC1=CN=C(C=C1)C1C=CC(=CC=1)CCCC1=NN(C(N1CC)=O)CC1C=CC(=CC=1)C(C)(C)C)(=O)=O
|
| InChi Key |
IRSFLNXJVJKMDT-UHFFFAOYSA-N
|
| InChi Code |
InChI=1S/C35H39N5O3S/c1-5-39-33(37-40(34(39)41)25-27-16-20-29(21-17-27)35(2,3)4)13-9-10-26-14-18-28(19-15-26)32-23-22-30(24-36-32)38-44(42,43)31-11-7-6-8-12-31/h6-8,11-12,14-24,38H,5,9-10,13,25H2,1-4H3
|
| Chemical Name |
N-[6-[4-[3-[1-[(4-tert-butylphenyl)methyl]-4-ethyl-5-oxo-1,2,4-triazol-3-yl]propyl]phenyl]pyridin-3-yl]benzenesulfonamide
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO : ~125 mg/mL (~204.99 mM)
|
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 2.08 mg/mL (3.41 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 20.8 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: ≥ 2.08 mg/mL (3.41 mM) (saturation unknown) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 20.8 mg/mL clear DMSO stock solution to 900 μL of 20% SBE-β-CD physiological saline solution and mix evenly. Preparation of 20% SBE-β-CD in Saline (4°C，1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. View More
Solubility in Formulation 3: ≥ 2.08 mg/mL (3.41 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution. |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 1.6399 mL | 8.1997 mL | 16.3994 mL | |
| 5 mM | 0.3280 mL | 1.6399 mL | 3.2799 mL | |
| 10 mM | 0.1640 mL | 0.8200 mL | 1.6399 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
